{
    "clinical_study": {
        "@rank": "92614", 
        "brief_summary": {
            "textblock": "The purpose of this protocol is to continue to treat patients with Wegener's granulomatosis\n      who have already entered the study, and to treat new patients.  The investigators will\n      attempt to correlate the clinical response with specific immunosuppressive effects of drug\n      administration.  The investigators are accumulating data on the optimal duration and side\n      effects of therapy."
        }, 
        "brief_title": "Treatment of Wegener's Granulomatosis With Cyclophosphamide", 
        "completion_date": "February 2002", 
        "condition": [
            "Vasculitis", 
            "Wegener's Granulomatosis"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Vasculitis", 
                "Wegener Granulomatosis"
            ]
        }, 
        "detailed_description": {
            "textblock": "The purpose of the protocol is to continue to treat patients with Wegener's granulomatosis\n      who have already entered the study, and to treat new patients.  The investigators will\n      attempt to correlate the clinical response with specific immunosuppressive effects of drug\n      administration.  The investigators are accumulating data on the optimal duration and side\n      effects of therapy.\n\n      Age Range: greater than 1 year"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Patients greater than 1 year of age with the clinical and pathological diagnosis of WG\n        whose illness presents a risk of permanent disability or death.  Examples of processes\n        that impart risk of permanent disability or death include:  peripheral and central nervous\n        system disease, cardiac involvement, glomerulonephritis, and vascular comprise of\n        gastrointestinal organs.\n\n        No women who are pregnant or intend to become pregnant.\n\n        No patients who have known malignancies.\n\n        Patients must be HIV negative."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": "200", 
        "firstreceived_date": "November 3, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00001155", 
            "org_study_id": "760042", 
            "secondary_id": "76-I-0042"
        }, 
        "intervention": {
            "intervention_name": "cyclophosphamide", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Cyclophosphamide"
        }, 
        "keyword": [
            "Vasculitis", 
            "Prednisone", 
            "Granuloma", 
            "Wegener's Granulomatosis", 
            "Cyclophosphamide", 
            "Renal Biopsy"
        ], 
        "lastchanged_date": "March 3, 2008", 
        "location": {
            "facility": {
                "address": {
                    "city": "Bethesda", 
                    "country": "United States", 
                    "state": "Maryland", 
                    "zip": "20892"
                }, 
                "name": "National Institute of Allergy and Infectious Diseases (NIAID)"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Treatment of Wegener's Granulomatosis With Cyclophosphamide", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 2", 
        "reference": [
            {
                "PMID": "8602705", 
                "citation": "Talar-Williams C, Hijazi YM, Walther MM, Linehan WM, Hallahan CW, Lubensky I, Kerr GS, Hoffman GS, Fauci AS, Sneller MC. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med. 1996 Mar 1;124(5):477-84."
            }, 
            {
                "PMID": "1739240", 
                "citation": "Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD, Rottem M, Fauci AS. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med. 1992 Mar 15;116(6):488-98."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00001155"
        }, 
        "source": "National Institutes of Health Clinical Center (CC)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Institute of Allergy and Infectious Diseases (NIAID)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "February 1976", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2002"
    }, 
    "geocoordinates": {
        "National Institute of Allergy and Infectious Diseases (NIAID)": "38.985 -77.095"
    }
}